ASPIVIX is pleased to announce a new partnership with AGHealth to launch Carevix®, its MHRA-approved non-traumatic suction cervical stabilizer, in the United Kingdom. This milestone marks asignificant advance in UK women’s healthcare, offering a modern and clinically validatedalternative to the traditional cervical tenaculum.
Carevix®, approved for use by the UK’s Medicines and Healthcare products RegulatoryAgency (MHRA), has been designed to minimize pain and reduce bleeding during intrauterine procedures such as coil-fitting and endometrial biopsies. Traditional tenaculum forceps—still commonly used—are known to cause discomfort, fear, and sometimes trauma for patients.
Peterborough City Hospital, part of the North West Anglia NHS Foundation Trust, became the first hospital in the UK to adopt Carevix® in 2024 through the Carevix® Ambassador Program. This initiative brought together 21 centers of excellence across 9 countries to evaluate the device in real-world settings. Results from the program showed high satisfaction among both clinicians and patients, with 96% of clinicians finding Carevix® easy to use and 94% overall patient satisfaction.
Fear of pain during IUD insertion remains a major barrier to adoption, affecting 30% to45% of women globally, an estimated 120 million women each year, primarily due to the useof the traditional cervical tenaculum. In addition to the Ambassador Program, the ADVANCE Women Study, a single-blinded,randomized, multicenter comparative trial, Carevix® demonstrated a 73% reduction in painand 78% reduction in bleeding during IUD placement compared to the standard tenaculumbecoming a new alternative for better patient experience.
AGHealth, a UK specialist distributor in women’s health, is known for introducing evidence-based, clinically relevant innovations to NHS and private sector providers. With a strongnetwork and a mission to improve women’s healthcare, AGHealth is an ideal partner forASPIVIX as it scales its presence in the UK.
